Yepuri, MDPrimary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease ...

Ocaliva recently failed to secure the FDA’s traditional approval for primary biliary cholangitis due to safety concerns.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...

Following a review of postmarket clinical trial data, the FDA identified several cases of serious liver injury among patients using Ocaliva, with some requiring liver transplants, according to a Dec.

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response ...

U.S. Indication for Livdelzi (seladelpar) 10mg capsules Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who ...

U.S. Indication for Livdelzi (seladelpar) 10mg capsules Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have ...